The big pharma is paying Hansoh $112 million upfront to place its bet on oral GLP-1 receptor agonist HS-1035, with another $1 ...

MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race ...

Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug helped reduce pain tied to a condition caused by a ...

Eli Lilly just gave investors several reasons to cheer.

Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...

Goldman Sachs’ Asad Haider likes the prospects for medical technology companies, mid-cap biotechs, drug distributors.

Lawsuits filed in New Jersey are part of hundreds of complaints against UnitedHealthcare, PBMs, and pharmaceutical giants ...

The Richmond company (Nasdaq: BIOA) will get a fraction of the money upfront from Novartis (NYSE: NVS) — up to $20 million, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

AnaptysBio's rosnilimab faces significant competition and uncertainty. See why ANAB stock's future hinges on Feb 2025 Phase ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.46% and ...

(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend ...